Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey
R. Andrew Harkins(The University of Texas MD Anderson Cancer Center), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), John P. Leonard(New York University), Jonathan W. Friedberg(University of Rochester), Peter Martin(Northwestern University), Jeffrey M. Switchenko(Emory University), Izidore S. Lossos(University of Miami), Kristie A. Blum(Emory University), Stephen M. Ansell(Mayo Clinic), Neha Mehta–Shah(The University of Texas MD Anderson Cancer Center), Carla Casulo(University of Rochester Medical Center), Sharvil Patel(Emory University), Brad S. Kahl(UW Health University Hospital), Patrick B. Johnston(Mayo Clinic in Arizona), Nancy L. Bartlett(Washington University in St. Louis), Patrick M. Reagan(University of Rochester), Brian K. Link(University of Iowa), Jean L. Koff(Emory University), Michelle J. Lee(Morehouse School of Medicine), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Matt Maurer(Mayo Clinic), Amanda F. Cashen(Washington University in St. Louis)
Cited by 11
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k